AlphAIAlphAI — Financial news for AI agents
wfmz.comOCT 72 min read$OPCH

Infusion therapy provider being acquired in $5.8 billion deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, expected to close in early 2027. CD&R will hold majority ownership, with McKesson holding a minority stake. Option Care Health shares were trading at $31.02, up from $23.34 before the acquisition news. The company will remain separate but will delist from Nasdaq post-deal.

Original reporting
wfmz.com
Published Oct 7, 2026, 5:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 7:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$OPCH
Bullish
high confidence
Mentioned
$OPCH
Relevance
9/10
AlphAI data visualization · based on wfmz.com
Decision brief

The 30-second read

$OPCHBullishHigh
01

Why it matters

The $5.8 billion acquisition by private equity firm CD&R and distributor McKesson creates a premium for shareholders and will remove OPCH from public markets, likely generating a short‑term price rally.

02

Market read

The deal represents a significant consolidation move in the U.S. healthcare services sector, with immediate price impact for OPCH and broader implications for peers.

03

What to watch

Potential antitrust review and the financing structure of CD&R's majority stake may affect deal certainty.

Relevance 9/10Novelty 9/10Timing: immediate, pre‑market today

Background

Option Care Health provides infusion therapy services, operating clinics across several states. The company was founded in 1979 and is currently listed on Nasdaq.

Company-level read

Ticker impact

$OPCHBullishHigh confidence
Context

Option Care Health (NASDAQ:OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, with shares trading at a premium to prior levels and the stock slated to delist.

Expected impact

upward pressure as investors price in the acquisition premium and buy‑back of shares

Evidence & confidence

Deal announced at $31.02 per share versus prior $23.34, representing a ~33% premium; market participants typically bid up the stock to the offer price ahead of closing.

Market effects

Sector

Consolidation in the infusion therapy and home health services sector may pressure peers' valuations.

Regional

Adds to M&A activity in the U.S. healthcare services market, potentially boosting related healthcare REITs.

Global

Large‑scale healthcare M&A signals continued investor appetite for fragmented health service providers worldwide.

Counterpoint

What could challenge this read

Deal could face regulatory hurdles or integration challenges, causing the stock to underperform the implied premium.

Key entities

  • company
    Option Care Health

    NASDAQ‑listed infusion therapy provider being acquired.

  • private equity
    CD&R

    Lead private equity sponsor acquiring a majority stake.

  • company
    McKesson Corporation

    Healthcare distribution giant taking a minority stake.

Read at source← All news

StoryCD&R and McKesson agree to acquire Option Care Health

Also covered by

4 outlets

Related articles

OCT 30
$BTSGHighAI 9/10

BrightSpring Soars 12% on Q3 Beat and Raised 2026 Guidance as Adjusted EBITDA Jumps 42%

BrightSpring Health Services (BTSG) stock rose 12% after Q3 earnings beat estimates, with revenue up 26% to $4.21B and adjusted EBITDA up 42% to $228M. The company raised its 2026 guidance. Gross profit per script increased 27%, and home health census grew 58% due to acquisitions from UnitedHealth's Amedisys and LHC Group. Option Care Health (OPCH) and CVS Health (CVS) report next week, which may indicate if BrightSpring's pricing gains are industry-wide.

finance.yahoo.com6 min
OCT 10
$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

tradingview.com1 min
OCT 10
$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

hoodline.com2 min
OCT 9
$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

finance.yahoo.com2 min
OCT 7
$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

finance.yahoo.com2 min